New hope for Hard-to-Treat breast cancer: phase 3 trial launches
NCT ID NCT06957886
First seen Jan 24, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests a new drug called BL-M07D1 against standard chemotherapy in 566 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. The goal is to see if BL-M07D1 can slow cancer growth or improve survival. Participants are randomly assigned to receive either the new drug or a standard chemo chosen by their doctor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.